Goldman Sachs
RNTX

Goldman Sachs’s Rein Therapeutics RNTX Stock Holding History

Goldman Sachs’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,660
Closed -$35K – 6404
2020
Q4 		$35K Buy
+1,660
New +$41.5K ﹤0.01% 5412
2020
Q3 		– Sell
-1,249
Closed -$29K – 5570
2020
Q2 		$29K Buy
+1,249
New +$20.4K ﹤0.01% 5109
2018
Q3 		– Sell
-597
Closed -$65K – 5828
2018
Q2 		$65K Buy
+597
New +$67.6K ﹤0.01% 5297
2017
Q3 		– Sell
-1,875
Closed -$418K – 6901
2017
Q2 		$418K Buy
+1,875
New +$412K ﹤0.01% 5239

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Goldman Sachs's RNTX Position: Q1 2021 in Review

Goldman Sachs sold out of Rein Therapeutics (RNTX) in Q1 2021, closing a stake of 1,660 shares — an estimated $35K sold.

Goldman Sachs first reported a position in RNTX in Q2 2017 and held it in 4 quarters. The position peaked at $418K in Q2 2017. 52 funds tracked by Wall St. Rank hold RNTX as of Q1 2021.

  • Goldman Sachs reported no remaining Rein Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Goldman Sachs sold 1,660 Rein Therapeutics shares in Q1 2021, an estimated $35K.
  • Goldman Sachs first reported a position in Rein Therapeutics in Q2 2017 and held it in 4 quarters.
  • Goldman Sachs's Rein Therapeutics position peaked at $418K in Q2 2017.
  • 52 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.